Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing
Abstract For oncology drugs that were approved by the US Food and Drug Administration (FDA) and required pharmacogenomic biomarker testing, we describe 1) the use of enrichment (biomarker-positive patients) and a randomized controlled design by pre-approval trials and 2) the treatment-by-biomarker i...
Main Authors: | Alexandre Vivot, Isabelle Boutron, Geoffroy Béraud-Chaulet, Jean-David Zeitoun, Philippe Ravaud, Raphaël Porcher |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2017-07-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-017-07358-7 |
Similar Items
-
Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
by: Jeeyun A. Kim, et al.
Published: (2021-03-01) -
Pharmacogenomic Biomarkers
by: Sandra C. Kirkwood, et al.
Published: (2002-01-01) -
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
by: Michael M. Boyiadzis, et al.
Published: (2018-05-01) -
Post-translational modifications of FDA-approved plasma biomarkers in glioblastoma samples.
by: Natalia A Petushkova, et al.
Published: (2017-01-01) -
Blockchain protocols in clinical trials: Transparency and traceability of consent [version 3; referees: 1 approved, 2 approved with reservations, 1 not approved]
by: Mehdi Benchoufi, et al.
Published: (2017-07-01)